Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS.

Trial Profile

Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL-Sync
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Nov 2017 Results of pooled post-hoc analysis from six phase III studies including this study, were published in The Journal of Rheumatology.
    • 08 Nov 2017 Results of a post-hoc analysis assessing associations of pain and physical function with Patient Global Assessment of disease activity in three phase III trials (ORAL Standard, ORAL Scan and ORAL Sync), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results of a pooled analysis of phase III trials (ORAL Solo, ORAL Start, ORAL Step, ORAL Scan, ORAL Sync and ORAL Standard) assessing Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top